WHAT IS CLAIMED IS:

1. Combination comprising a dipeptidylpeptidase-IV (DPP-IV) inhibitor and at least one peroxisome proflierator-activated receptor α (PPARα).

2. A pharmaceutical composition comprising a DPP-IV inhibitor in free or pharmaceutically acceptable salt form, and at least one further PPARα compound or the pharmaceutically acceptable salt of such a compound and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

3. The pharmaceutical composition according to claim 1, wherein the further PPARα compound is selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate or the pharmaceutically acceptable salt of such a compound.

4. The pharmaceutical composition according to claim 1, which is a fixed combination.

5 The pharmaceutical composition according to claim 1, which is a combined preparation.

6. The pharmaceutical composition according to claim 5 which is a combined preparation for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by DPP-IV or PPARα.

7. The combination according to claim 1 or a pharmaceutical composition according to any one of claims 2 to 6, wherein the DPP-IV inhibitor is a *N*-(*N'*-substituted glycyl)-2-cyanopyrrolidine of formula (I)



(I)

wherein R is:

a) $R_1R_{1a}N(CH_2)_m$-,

wherein

R_1 is a pyridinyl or pyrimidinyl moiety optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or

nitro; or phenyl optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen;

R_{1a} is hydrogen or (C_{1-8})alkyl; and

m is 2 or 3;

b) (C_{3-12})Cycloalkyl optionally mono-substituted in the 1-position with (C_{1-3})hydroxyalkyl;

c) $R_2(CH_2)_n$-,

wherein either

R_2 is phenyl optionally mono- or independently di- or, independently, tri-substituted with lower alkyl, lower alkoxy, halogen or phenylthio optionally mono-substituted in the phenyl ring with hydroxymethyl; or is (C_{1-8})alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or pluri-substituted with (C_{1-8})alkyl; a pyridinyl or naphthyl moiety optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen; cyclohexene; or adamantyl; and

n is 1-3; or

R_2 is phenoxy optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen; and

n is 2 or 3;

d) $(R_3)_2CH(CH_2)_2$-, wherein each R_3, independently, is phenyl optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen;

e) $R_4(CH_2)_p$-,

wherein

R_4 is 2-oxopyrrolidinyl or (C_{2-4})alkoxy; and

p is 2-4;

f) isopropyl optionally mono-substituted in 1-position with (C_{1-3})hydroxyalkyl;

g) R_5, wherein R_5 is indanyl, a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl, a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or pluri-substituted with (C_{1-8})alkyl, adamantyl or (C_{1-8})alkyl optionally mono- or, independently, pluri-substituted with hydroxy, hydroxymethyl or phenyl optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen;

h) a substituted adamantyl

in free form or in acid addition salt form.

8. The combination according to claim 1 or a pharmaceutical composition according to any one of claims 2 to 6, wherein the DPP-IV inhibitor a compound of formula (I) which is selected from

(S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine; and

(S)-1-{2-[5-cyanopyridin-2-yl)amino]ethyl-aminoacetyl}-2-cyano-pyrrolidine;

in free form or in acid addition salt form.

9. The combination according to claim 1 or a pharmaceutical composition according to any one of claims 2 to 6, wherein the DPP-IV inhibitor is selected from

(*S*)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine; and

(*S*)-1-{2-[5-cyanopyridin-2-yl)amino]ethyl-aminoacetyl}-2-cyano-pyrrolidine,

and the further PPARα compound is selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate,

or the pharmaceutically acceptable salt of such a compound.

10. A method of treating a condition mediated by DPP-IV or PPARα comprising administering to a warm-blooded animal in need thereof jointly therapeutically effective amounts of a DPP-IV inhibitor in free or pharmaceutically acceptable salt form and at least one PPARα compound, or the pharmaceutically acceptable salts of such compounds.

11. The method of claim 10, wherein the condition is dyslipidemia.

12. The method of claim 10, wherein the condition is diabetes.

13. The method of claim 12, wherein the condition is type II diabetes.

14. The method of claim 10, wherein the condition is obesity.

15. A combination or pharmaceutical composition according to any one of the claims 1 to 9, for use as a medicament.

16. Use of a DPP-IV inhibitor in free or pharmaceutically acceptable salt form in combination with at least one further PPARα compound in free or pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment a condition mediated by DPP-IV or PPARα.

17. Use of a DPP-IV inhibitor selected from

(*S*)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine; and

(*S*)-1-{2-[5-cyanopyridin-2-yl)amino]ethyl-aminoacetyl}-2-cyano-pyrrolidine,

in free or pharmaceutically acceptable salt form in combination with at least one further PPARα compound selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate, or the pharmaceutically acceptable salt of such a compound for the manufacture of a medicament for the treatment a condition mediated by DPP-IV or PPARα.

18. Use of a pharmaceutical composition according to any one of claims 2 to 6 for the manufacture of a medicament for the treatment a condition mediated by DPP-IV or PPARα.

19. Use according to any one of claims 16 to 18, wherein the condition mediated by DPP-IV or PPARα, is selected from diabetes, type 2 diabetes mellitus, conditions of IGT, conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity, dyslipidemia and osteoporosis

20. Use according to any one of claims 16 to 18, wherein the condition mediated by DPP-IV or PPARα, is selected from type 2 diabetes, impaired glucose tolerance, obesity and dyslipidemia.

21. A commercial package comprising as active agents a combination of a DPP-IV inhibitor and a PPARα compound together with instructions for simultaneous, separate or sequential use thereof in the prevention, delay of progression or treatment of a condition mediated by DPP-IV or PPARα.

22. A kit of parts comprising

(a) an amount of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof in a first unit dosage form;

(b) an amount of at least one PPARα compound or the pharmaceutically acceptable salt thereof ,

in the form of two or three or more separate units of the components (a) and (b).

23. A kit of parts according to claim 22 or a commercial package according to claim 21, wherein the DPP-IV inhibitor is selected from

(*S*)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine; and

(*S*)-1-{2-[5-cyanopyridin-2-yl)amino]ethyl-aminoacetyl}-2-cyano-pyrrolidine,

and the further PPARα compound is selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate